Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The single-agent activity of MEK inhibitors in MAPK or CDK4/6 inhibitors in cyclin pathway aberrant tumors has been limited. The combination of trametinib and palbociclib demonstrates safety, tolerability, and clinical activity in a histology-independent manner, representing a therapeutic approach for patients harboring co-occurring aberrations.See related article by Kato et al., p. 2792.

Keyphrases

end stage renal disease
cell cycle
ejection fraction
chronic kidney disease
newly diagnosed
signaling pathway
palliative care
peritoneal dialysis
pi k akt
prognostic factors
open label
gene expression
clinical trial
patient reported outcomes
cell death
dna methylation
cell cycle arrest
genome wide